Earnings

Aligos Therapeutics Q3 EPS $(2.09) Beats $(2.28) Estimate, Sales $2.830M Miss $5.543M Estimate

Nov 6, 2026 · 08:36 AM ET· updated 1h ago

Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(2.09) per share which beat the analyst consensus estimate of $(2.28) by 8.33 percent. This is a 31.25 percent increase over losses of $(3.04) per share

Why It Matters

Aligos lost less money per share than people expected, which is good. But the company made way less sales money than hoped, which is concerning.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ALGS4.49

-0.02 (-0.44%)

MMM186.21

-1.56 (-0.83%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.